



MiHKAL
— GmbH —

Company

Presentation

Non-confidential



Hegenheimermattweg 125

CH-4123 Allschwil

www.mihkal.com

The first and only psychedelic drug development start-up in Europe



Dr. Matthias Grill

CEO and
Founder of MiHKAL
Chemist




Tamara Hell

Co-Founder and
CFO
Biologist


Global Depression rises drastically

still **23%**



Market shares of leading antidepressants – 16.6 Billion in 2023

50%



Global acceptance for

Psychedelics:



Psilocybin against Treatment resistant depression (TRD)

MDMA against PTSD



FDA AdCom in June 4th 2024


Due to severe side effects of classic antidepressants along with raising market reluctance

More and more critics about effectiveness of classic antidepressants → Existence of Treatment resistant depression (TRD)

Our unique product: Modeling the effects of MDMA




Increase in systolic blood pressure*



Medical issues correlated:

- Rapid increase of blood pressure
- Patients can experience «high»
- Increase of body temperature
- 2 doses necessary


Increase in systolic blood pressure**




- Instead of two MDMA split doses, only one dose of MKL001 is expected to provide the same duration of effect
- Due to an expected slower on- & offset of the drug and lower C_{max} , less side effects and lower addiction profile are expected (slow and steady release and metabolization of the drug)
- Expecting less cardiovascular issues due to slow and steady release and metabolization of the drug
- Reduced addiction potential!

* *Neuropsychopharmacology* volume 45, pages 462–471 (2020)
125 mg MDMA p.o.
Overall effects 4.4 +/- 1.7 hours

Our unique product MKL001 : 2 independent types of therapy feasible



MKL001



Fast delivery for short inhouse therapy sessions (nasal/buccal)

Slow release and prolonged effect for persistent treatment regimens (oral) at home

Target Product Profile

- Less side-effects
- Lower addiction profile compared to MDMA
- Less abuse potential
- Tunable drug release for fast/retarded applications
- Possible indications: PTSD, TRD, anorexia nervosa/eating disorders, alcohol-/drug abuse
- Applicable to a wide range of patients



Patent assets



- *Novel Safrylamine derivates having prodrug properties (MDMA-Lys = MDMA prodrugs) - **WO2022053696 ****
- *Novel nootropic prodrugs of phenethylamine (= MDMA derivatives) - **WO2024056678***
- *Novel N,N,-Dimethyltryptamine (DMT) derivatives and uses thereof (= DMT prodrugs) - **EP22211625.3***
- *Improved method for the production of LSD and novel derivatives thereof (= LSD-derivatives) - **WO2022008627 ****

Patent continued by Compass pathways:

- *Novel Psilocin derivates having prodrug properties - **WO2022038299***
 - **Patent developed by MiHKAL**
 - **3 years collaboration MiHKAL / Compass**
 - **Patent nationalized in 52 countries**
- **Reassignment of MDMA and LSD Patent to MiHKAL**

*Reassigned from Compass Pathways